Background
==========

The immunogenicity of current human immunodeficiency virus-1 (HIV-1) canarypox vaccines is weak and needs to be improved. Ligation of OX40 (CD134), a member of tumor necrosis factor receptor superfamily (TNFRSF), by its ligand OX40L (CD252), a tumor necrosis factor superfamily (TNFSF) molecule, has been demonstrated to provide a pivotal costimulatory signal to enhance CD4 T cell help of humoral and cytotoxic T cell immune responses. The present study examined whether an OX40L expressing vector could boost the immunogenicity of the HIV-1 canarypox vaccine, vCP1452, in mice.

Methods
=======

Female Balb/c mice were vaccinated 3 times with 2-week intervals according to the following schedule: group 1: naive unimmunized mice; group 2: 10 pfu of vCP1452 + 10 pfu empty vector ALVAC II; group 3: 10 pfu of vCP1452 + 10 pfu vCPmOX40L; group 4: 10 pfu of vCP1452 + 5 × 10 pfu vCPmOX40L + 5 × 10 pfu vCPmCD40L. Six weeks after the last immunization, mice were sacrificed and spleens and sera were collected for immunological analysis, including IFN-γ ELISPOT, tetramer staining, ICS, CFSE proliferation assay, and anti-Gag ELISA.

Results
=======

Co-immunization of mice with OX40L-expressing canarypox and vCP1452 augmented HIV-1 specific CD8 T cell responses in terms of frequency and cytokine expression. OX40L-expressing canarypox enhanced the frequency of antigen specific CD8 T cells with an effector (CD127 CD62L) phenotype, which was associated with an *ex vivo*expansion of HIV-1 specific CD4 T cells. Surprisingly, OX40L did not enhance antibody responses elicited by the HIV-1 canarypox vaccine. We saw no added benefit by combining OX40L and CD40L vectors as an adjuvant strategy for vCP1452.

Conclusion
==========

Our results indicate that, similar to CD40L, OX40L can enhance the cellular but not humoral immunogenicity of HIV-1 canarypox vaccines. In summary, our findings show that OX40L can be used as a molecular adjuvant to enhance T cell immune responses.
